ClinicalTrials.gg
CompletedNCT00591578Updated Feb 2, 2012Results posted

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

A Phase 3 interventional study of Azilsartan Medoxomil and Azilsartan Medoxomil in Hypertension, sponsored by Takeda. Completed at 88 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
984
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
6th of 21
984 · median 566
Started
2007
with 6 others
Phase 3
17 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 6th largest by enrollment, is one of 7 that started in 2007, is one of 17 in phase 3, and was the 2nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization (WHO), hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.

This study is being conducted to determine whether administration of azilsartan medoxomil in subjects with essential hypertension is more efficacious in reducing systolic blood pressure than valsartan.

Study participation is anticipated to be approximately 7 months. Outside of the study center, participants will be required to wear an ambulatory blood pressure monitoring device at 24 hour intervals.

Following completion of the 6-month double-blind treatment period, all available subjects will be offered the option to continue in a 28-week extension study with open-label azilsartan medoxomil 40 mg.

For the extension study, participants will take azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 28 weeks. Hydrochlorothiazide 12.5 mg or 25 mg or any other antihypertensive (except angiotensin II receptor blockers) may be added in a step-wise fashion to maintain blood pressure within target \<140/90 mmHg for non-diabetic subjects and \<130/80 mmHg for diabetic subjects

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood pressure
  • blood pressure monitoring, ambulatory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Essential hypertension (defined as sitting trough clinic systolic blood pressure between 150 and 180 mm Hg inclusive at Day minus 1 and 24-hour mean systolic blood pressure between 130 and 170 mm Hg inclusive at Day 1).
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not for inclusion into this study by the investigator.
  4. Willing to discontinue current antihypertensive medications at the Screening Day minus 21 visit. If the subject is on amlodipine prior to Screening, the subject is willing to discontinue this medication at Screening Day minus 28.

Exclusion criteria

Exclusion Criteria

  1. Sitting trough clinic diastolic blood pressure greater than 114 mm Hg at Day minus 1.
  2. The subject has a baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.
  3. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.
  4. Hypersensitive to angiotensin II receptor blockers.
  5. Recent history (within the last 6 months) of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  6. cardiac conduction defects (eg, 3rd degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or flutter).
  7. Hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  8. Secondary hypertension of any etiology.
  9. Non-compliant (less than 70% or greater than 130%) with study medication during placebo run-in period.
  10. Severe renal dysfunction or disease (based on calculated less than 30 mL per min/1.73m2) at Screening.
  11. Known or suspected unilateral or bilateral renal artery stenosis.
  12. History of drug or alcohol abuse within the past 2 years.
  13. Previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug. (This criterion does not apply to those subjects with basal cell or Stage 1 squamous cell carcinoma of the skin).
  14. Type 1 or poorly controlled type 2 diabetes mellitus (glycosylated greater than 8.0%) at Screening.
  15. Hyperkalemia as defined by the central laboratory normal reference range at Screening.
  16. Upper arm circumference less than 24 cm or greater than 42 cm.
  17. Works night (3rd) shift (defined as 11PM to 7AM).
  18. level of greater than 2.5 times the , active liver disease, or jaundice at Screening.
  19. Currently is participating in another study or has participated in an investigational study within 30 days prior to randomization.
  20. Any other serious disease or condition at Screening (or Randomization) that would compromise subject safety, might affect , or make it difficult to successfully manage and follow the subject according to the protocol.
  21. Randomized in a previous azilsartan medoxomil study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
984 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 40 mg QD

    Drug: Azilsartan Medoxomil

  • Experimental
    Azilsartan Medoxomil 80 mg QD

    Drug: Azilsartan Medoxomil

  • Active comparator
    Valsartan 320 mg QD

    Drug: Valsartan

Interventions

  • Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.

    Also known as: TAK-491, Edarbi

  • Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.

    Also known as: TAK-491, Edarbi

  • Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.

    Also known as: Diovan

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 24.

Secondary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 24 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 24.

  2. Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 24.

  3. Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

    The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 24 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 24.

  4. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 24.

  5. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 24.

  6. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 24.

  7. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 24.

  8. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 24.

  9. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 12-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 24.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 24.

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 24.

  12. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.

    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 24, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 24.

  13. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 24, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 24.

  14. Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.

    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 24, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

    Time frame: Baseline and Week 24.

07

Results

Posted Apr 19, 2011
Limitations and caveats
For the Non-Serious Adverse Event Table, the total number of participants affected is based on the AEs with ≥5% in each phase, calculated separately.

Participant flow

Participants enrolled at 103 investigative sites from 09 November 2007 to 03 September 2009 (double-blind phase) and 04 March 2009 to 13 March 2010 (open-label extension phase). A total of 984 participants were randomized into the double-blind treatment phase, of which 170 participants entered into the open-label extension phase.

Double-Blind Treatment Phase
Participant flow — Double-Blind Treatment Phase
MilestoneAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Started327329328
Completed249249244
Not completed788084
Withdrew: Adverse event202619
Withdrew: Protocol violation323
Withdrew: Lost to follow-up121211
Withdrew: Withdrawal by subject222222
Withdrew: Pregnancy100
Withdrew: Lack of efficacy16925
Withdrew: Other494
Open-Label Extension Phase
Participant flow — Open-Label Extension Phase
MilestoneAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Started551150
Completed491050
Not completed6100
Withdrew: Adverse event350
Withdrew: Lost to follow-up140
Withdrew: Withdrawal by subject110
Withdrew: Other100

Outcome measures

PrimaryChange From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-14.93 ± 0.698-15.32 ± 0.715-11.29 ± 0.707
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -3.64 · 95% CI -5.59 to -1.69
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Unadjusted p-value presented. Overall 0.05 level of significance for multiple comparisons controlled using stepwise testing procedure.) · Mean difference (final values): -4.03 · 95% CI -6.01 to -2.06
SecondaryChange From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 24 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.-14.86 ± 0.948-16.92 ± 0.966-11.59 ± 0.949
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.015 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.27 · 95% CI -5.90 to -0.63
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -5.34 · 95% CI -8.00 to -2.68
SecondaryChange From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-9.23 ± 0.459-9.77 ± 0.470-7.07 ± 0.465
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.16 · 95% CI -3.44 to -0.88
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.69 · 95% CI -3.99 to -1.40
SecondaryChange From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 24 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure-7.16 ± 0.554-7.41 ± 0.565-4.65 ± 0.555
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.52 · 95% CI -4.06 to -0.98
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.76 · 95% CI -4.32 to -1.21
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-15.39 ± 0.732-15.80 ± 0.749-11.91 ± 0.741
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.49 · 95% CI -5.53 to -1.44
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.90 · 95% CI -5.96 to -1.83
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-9.61 ± 0.493-10.11 ± 0.504-7.44 ± 0.499
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.002 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.17 · 95% CI -3.54 to -0.79
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.67 · 95% CI -4.06 to -1.28
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-13.31 ± 0.777-13.95 ± 0.795-9.52 ± 0.786
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.79 · 95% CI -5.96 to -1.62
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -4.44 · 95% CI -6.63 to -2.24
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-8.06 ± 0.526-8.90 ± 0.539-6.06 ± 0.533
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.008 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.00 · 95% CI -3.48 to -0.53
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.84 · 95% CI -4.33 to -1.35
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-15.64 ± 0.764-16.20 ± 0.782-12.20 ± 0.774
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.002 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.44 · 95% CI -5.57 to -1.30
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -4.01 · 95% CI -6.16 to -1.85
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-9.70 ± 0.522-10.26 ± 0.534-7.53 ± 0.528
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.003 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.18 · 95% CI -3.63 to -0.72
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.73 · 95% CI -4.20 to -1.25
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-13.74 ± 0.851-13.83 ± 0.871-10.36 ± 0.861
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.005 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.38 · 95% CI -5.76 to -1.00
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.005 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -3.47 · 95% CI -5.87 to -1.06
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 24 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 24.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-9.37 ± 0.617-9.65 ± 0.632-7.06 ± 0.625
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.009 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.31 · 95% CI -4.04 to -0.59
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · ANCOVA · p = 0.004 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). The unadjusted p-value is presented.) · Mean difference (final values): -2.59 · 95% CI -4.34 to -0.84
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 24, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.
percentage of participantsAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.56.059.246.9
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.016 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.46 · 95% CI 1.07 to 2.00Includes only those participants with a baseline and at least one post-baseline value.
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.002 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.63 · 95% CI 1.19 to 2.23Includes only those participants with a baseline and at least one post-baseline value.
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 24, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.
percentage of participantsAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.72.474.065.8
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.041 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.46 · 95% CI 1.02 to 2.10Includes only those participants with a baseline and at least one post-baseline value.
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.015 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.58 · 95% CI 1.09 to 2.28Includes only those participants with a baseline and at least one post-baseline value.
SecondaryPercentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 24, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

Time frame:
Baseline and Week 24.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.
percentage of participantsAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QD
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.50.254.741.3
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = 0.018 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.46 · 95% CI 1.07 to 1.99Includes only those participants with a baseline and at least one post-baseline value.
  • Azilsartan Medoxomil 80 mg QD vs Valsartan 320 mg QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 1.70 · 95% CI 1.24 to 2.33Includes only those participants with a baseline and at least one post-baseline value.

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 40 mg QD—8/327 (2.4%)77/327 (23.5%)
Azilsartan Medoxomil 80 mg QD—5/329 (1.5%)74/329 (22.5%)
Valsartan 320 mg QD—8/326 (2.5%)53/326 (16.3%)
Open Label Extension—4/170 (2.4%)16/170 (9.4%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOpen Label Extension
Myocardial infarctionCardiac disorders0/3271/3290/3261/170
Cholecystitis acuteHepatobiliary disorders1/3270/3290/3261/170
Inguinal hernia, obstructiveGastrointestinal disorders0/3270/3290/3261/170
Hip fractureInjury, poisoning and procedural complications0/3270/3290/3261/170
Silent myocardial infarctionCardiac disorders0/3271/3291/3260/170
Coronary artery diseaseCardiac disorders0/3270/3291/3260/170
Abdominal painGastrointestinal disorders0/3270/3291/3260/170
ErysipelasInfections and infestations0/3270/3291/3260/170
Scrotal abscessInfections and infestations0/3270/3291/3260/170
FallInjury, poisoning and procedural complications0/3270/3291/3260/170
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDOpen Label Extension
HeadacheNervous system disorders33/32729/32928/3269/170
DizzinessNervous system disorders27/32729/32915/3268/170
Urinary tract infectionInfections and infestations26/32725/32916/32610/170

Baseline characteristics

Age, Customized
Age, Customized(participants)Azilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDTotal
<45 years (Double Blind Phase)433931113
Between 45 and 64 years (Double Blind Phase)181208199588
≥65 years (Double Blind Phase)1038298283
<45 years (Open Label Phase)108018
Between 45 and 64 years (Open Label Phase)2568093
≥65 years (Open Label Phase)2039059
Sex/Gender, Customized
Sex/Gender, Customized(participants)Azilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDValsartan 320 mg QDTotal
Female (Double Blind Phase)163160152475
Male (Double Blind Phase)164169176509
Female (Open Label Phase)3457091
Male (Open Label Phase)2158079
08

Study locations

88 sites
  • Huntsville, Alabama, United States
  • Glendale, Arizona, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Tuscon, Arizona, United States
  • Beverly Hills, California, United States
  • Burbank, California, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Paramount, California, United States
  • San Diego, California, United States
  • Santa Monica, California, United States
  • Spring Valley, California, United States
  • Tustin, California, United States
  • Vista, California, United States
  • Westlake Village, California, United States
  • Ridgefield, Connecticut, United States
  • Newark, Delaware, United States
  • Washington, District of Columbia, United States
  • DeLand, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Hollywood, Florida, United States
  • Inverness, Florida, United States
  • Jacksonville, Florida, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Gurnee, Illinois, United States
  • Morton, Illinois, United States
  • Park Ridge, Illinois, United States
  • Avon, Indiana, United States
  • Bloomington, Indiana, United States
  • Crestview Hills, Kentucky, United States
  • Baltimore, Maryland, United States
  • Columbia, Maryland, United States
  • Brockton, Massachusetts, United States
  • West Yarmouth, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Florissant, Missouri, United States
  • Kansas City, Missouri, United States
  • St. Peters, Missouri, United States
  • Washington, Missouri, United States
  • Wentzville, Missouri, United States
  • Charlotte, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Shelby, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Delaware, Ohio, United States
  • Mogadore, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Zanesville, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Bridgeville, Pennsylvania, United States
  • Downingtown, Pennsylvania, United States
  • Jenkintown, Pennsylvania, United States
  • Lansdale, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Spartanburg, South Carolina, United States
  • Kingsport, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Pearland, Texas, United States
  • Rosenberg, Texas, United States
  • San Antonio, Texas, United States
  • Riverton, Utah, United States
  • Salt Lake City, Utah, United States
  • West Jordan, Utah, United States
  • Arlington, Virginia, United States
  • Burke, Virginia, United States
  • Norfolk, Virginia, United States
  • Lakewood, Washington, United States
  • Port Richard, Washington, United States
  • Menomonee Falls, Wisconsin, United States
  • Santiago, Chile
  • Temuco, Chile
  • Cabo San Lucas, Mexico
  • Colonia Escandon, Mexico
  • Culiacan, Mexico
  • Mexico City, Mexico
  • Monterrey Nuevo Leon, Mexico
  • Morelia, Mexico
  • Queretaro, Mexico
  • Chiclayo, Peru
  • Lima, Peru
09

References and documents

Publications

  • Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, Handley A, Kupfer S. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul;13(7):467-72. doi: 10.1111/j.1751-7176.2011.00482.x. Epub 2011 Jun 20. PubMed 21762358 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Sep 2009 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2007
First posted
Jan 11, 2008
Start
Dec 2007
Primary completionActual
Sep 2009
CompletionActual
Mar 2010
Results first posted
Apr 19, 2011
Last update
Feb 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00591578
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 11, 2008
Start date
Dec 2007
Primary completion
Sep 2009
Completion
Mar 2010
Results posted
Apr 19, 2011
Last update
Feb 2, 2012

Study contacts

Executive Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion